Novel strategies for systemic treatment of endometrial cancer

Expert Opinion on Investigational Drugs

Volumn 9, Issue 12, 2000, Pages 2831-2853

  Elit, L ^a   Hirte, H ^a  

^a JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

Biological therapy; Chemotherapy; Endometrial cancer; Hormonal therapy

Indexed keywords

AMONAFIDE; AMSACRINE; ANASTROZOLE; ANTINEOPLASTIC AGENT; ARIMEDEX; ARZOXIFENE; CARBOPLATIN; CISPLATIN; DACTINOMYCIN; DIANHYDROGALACTITOL; DIAZIQUONE; DOXORUBICIN; ECHINOMYCIN; ESTROGEN RECEPTOR; ETOPOSIDE; FLUDARABINE; GESTAGEN; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYPROGESTERONE CAPROATE; IFOSFAMIDE; LETROZOLE; MEDROXYPROGESTERONE ACETATE; PACLITAXEL; PIPERAZINEDIONE; PROGESTERONE; RALOXIFENE; TAMOXIFEN; TENIPOSIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

BODY WEIGHT DISORDER; BONE MARROW TOXICITY; BULIMIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG RECEPTOR BINDING; ENDOMETRIUM CANCER; FEMALE; FLUID RETENTION; HUMAN; MAJOR CLINICAL STUDY; MYOMETRIUM; NEUROTOXICITY; OTOTOXICITY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REVIEW; SIDE EFFECT; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0033667760     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.12.2831     Document Type: Review

References (175)

1. Canadian Cancer Statistics 1999
2. Carcinoma of the corpus uteri
3. Systemic treatment of advanced and recurrent endometrial carcinoma: Current status and future directions
4. A Phase 3 randomized study of surgery versus surgery plus adjunctive therapy in intermediate risk endometrial adenocarcinoma (GOG 99)
5. Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma
6. Effects of progestational agents in treatment of endometrial carcinoma
7. Endometrial cancer
8. Treatment of advanced endometrial adenocarcinoma with a combined cytotoxic therapy. Predictive value of cytosol estrogen and progestin receptor levels
9. Corpus: Epithelial tumors
10. A randomized study of medroxyprogesterone acetate (MPA) 200 mg versus 1000mg in the treatment of advanced or recurrent carcinoma of the endometrium
11. A comparison of medroxyprogesterone serum concentrations by oral or intramuscular route in patients with persistent or recurrent endometrial carcinoma
12. Progestin therapy of endometrial, breast and ovarian carcinoma
13. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: A gynecologic oncology group study
14. Progestagens for endometrial cancer
15. Adjuvant chemotherapy for high-risk endometrial cancer
16. Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer
17. Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: A randomized Phase II study of the EORTC gynecological cancer cooperative group
18. Adjuvant therapy in high-risk endometrial adenocarcinoma
19. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage 1 and occult stage II: A gynecologic oncology group study
20. Cisplatin, adriamycin, etoposide, megestrol acetate versus melphalan, 5-fluorouracil, medroxyprogestione acetate in the treatment of endometrial carcinoma
21. Combination chemotherapy for advanced endometrial cancer: An evaluation of three regimens
22. Multidrug treatment of advanced and recurrent endometrial carcinoma: A gynecologic oncology group study
23. Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status
24. Randomized Phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma
25. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women
26. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40
27. Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin
28. Reversal of the multidrug resistance (MDR) phenotype with megestrol acetate
29. Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: A gynecologic oncology group study
30. Ineffectiveness of tamoxifen in advanced endometrial carcinoma after failure of progesting treatment
31. Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma
32. Treatment of advanced endometrial adenocarcinoma with tamoxifen
33. Multicentre Phase II study of the selective estrogen receptor modulator (SERM) Ly 353381 in advanced or recurrent endometrial cancer - Objective responses in progestagen sensitive patients
34. Possible role of goserelin, an LH-RH agonist in the treatment of gynecological cancers
35. A new treatment for endometrial cancer with gonadotrophin releasing-hormone analogue
36. Long-term follow-up of gonadotropin-releasing hormone analog treatment for recurrent endometrial cancer
37. A Phase II study of leuprolide in advanced/recurrent endometrial cancer
38. A Phase II trial of anastrozole in advanced recurrent or persistent endometrial cancer: A gynecologic oncology group study
39. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934)
40. Future directions in gynecologic cancers
41. Whole abdominal radiotherapy versus combination chemotherapy with doxorubicin and cisplatin in advanced endometrial carcinoma (Phase III): Gynecologic oncology group study no. 122
42. HER-2/neu, p53 and DNA analysis as prognosticators for survival in endometrial carcinoma
43. p53 staining as a prognostic indicator in endometrial carcinoma
44. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias
45. Mutations of MSH3 in endometrial cancer and evidence for its role in heteroduplex repair
46. Fhit alterations in endometrial carcinoma and hyperplasia
47. Genetics of ovarian carcinoma
48. Mutations of the Ki-ras oncogene in carcinoma of the endometrium
49. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancer: Correlation with overall survival
50. Expression of epidermal growth factor family proteins and epidermal growth factor receptor in human endometrium
51. Oncogene alterations in endometrial carcinoma
52. High level expression of fms roto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas
53. Independent prognostic importance of microvessel density in endometrial carcinoma
54. Identification and localization of alternately spiced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines
55. Vascular endothelial growth factor messenger ribonucleic acid expression in human ovarian and endometrial cancer
56. Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma
57. Distribution of integrin cell adhesion molecules in endometrial cancer
58. Expression of CD44 in normal human versus tumor endometrial tissues: Possible implication of reduced expression of CD44 in lymph-vascular space involvement of cancer cells
59. Matrix metalloproteinases and their inhibitors in tumor progression
60. Matrix metalloproteinase inhibition: A review of anti-tumor activity
61. Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas
62. Tyrosine kinase inhibitors: From the emergence of targets to their clinical development
63. Targeting farnesyltransferase: Is ras relevant?
64. Shifting the cancer paradigm: Must we kill to cure?
65. Hydroxyprogesterone caproate therapy in advanced endometrial cancer
66. Progestational agents in the treatment of carcinoma of the endometrium
67. Medroxyprogesterone in the management of primary and recurrent or metastatic uterine adenocarcinoma
68. Gestagens and endometrial carcinoma
69. Endometrial carcinoma: Steroid receptors and response to medroxyprogesterone acetate
70. Oral medroxyprogesterone acetate in advanced or recurrent endometrial carcinoma: Results of therapy and correlation with estrogen and progesterone levels
71. High dose megestrol acetate in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group (GOG) study
72. Hormonotherapie adjuvante par medroxyprogesterone dans le traitement de l'adenocarcinome endometrial au stage I
73. Adjuvant progesteron therapy for stage I endometrial carcinoma
74. A controlled clinical study of adjuvant medroxyprogesterone acetate (MPA) therapy in pathological stage I endometrial cancer with myometrial invasion
75. Adjuvant progesterone therapy in the primary definitive treatment of endometrial cancer
76. A randomized trial of progestogens in the primary treatment of endometrial carcinoma
77. A randomized trial of adjuvant progestogen in early endometrial cancer
78. Endometrial cancer: Approach to development of effective chemotherapy
79. Perspectives on research in gynecologic oncology: Treatment protocols
80. A Phase II trial of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study
81. A Phase II study of ifosfamide in endometrial cancer
82. Treatment of advanced endometrial adenocarcinoma with cis-dichlorodiammine platinum (II) after intensive prior therapy
83. Cisplatin chemotherapy for disseminated endometrial cancer
84. Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study
85. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced and recurrent endometrial carcinoma: A gynecologic oncology group study
86. A Phase II study of cisplatinum for recurrent corpus cancer
87. Phase II evaluation of carboplatin in advanced endometrial carcinoma
88. Carboplatin therapy in advanced endometrial cancer
89. Treatment of advanced or recurrent endometrial carcinoma with single agent carboplatin
90. Hexamethylmelamine chemotherapy for disseminated endometrial cancer
91. Hexamethylmelamine as first-line therapy in the treatment of advanced or recurrent carcinoma of the endometrium: A Phase II trial of the gynecologic oncology group
92. Phase II trial of adriamycin in the treatment if advanced or recurrent endometrial carcinoma: A gynecologic oncology group study
93. Epirubicin in advanced endometrial adenocarcinoma: A Phase II study of the Grupo Ginecologico Espanol para el Tratamiento Oncologico (GGETO)
94. Phase II study of idarubicin in advanced endometrial carcinoma
95. Esorubicin in advanced endometrial cancer: An ineffective and potentially toxic therapy. A Southwest Oncology Group study. Invest
96. Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: Study of the clinical screening group of the European Organization for Research and Treatment of Cancer (EORTC)
97. Mitoxantrone in adenocarcinoma of the endometrium: A Southwest oncology group study
98. Mitoxantrone for carcinoma of the endometrium: A Phase II trial of the gynecologic oncology group
99. Phase II study of mitoxantrone in advanced or metastatic endometrial carcinoma
100. Phase II study of the pegylated liposomal doxorubicin (Doxil(TM)) in previously treated metastatic endometrial cancer: A gynecologic oncology group study
101. Methotrexate in advanced enodmetrial carcinoma. A Phase II trial of the gynecologic oncology group
102. Cytembena treatment of advanced gynecologic carcinomas
103. Phase II trial of oral Etoposide in recurrent or refractory endometrial adenocarcinoma: A Southwest oncology group study
104. Phase II trial of etposide in the management of advanced or recurrent endometrial carcinoma: A gynecologic oncology group study
105. A Phase II trial of vincristine given as a weekly intravenous bolus in advanced or recurrent endometrial carcinoma: A Phase II trial of the gynecologic oncology group
106. Vincristine infusion in refractory gynecologic malignancies
107. A trial of continuous-infusion vinblastine in refractory endometrial adenocarcinoma
108. A Phase II trial of vinblastine in patients with advanced or recurrent endometrial carcinoma. A Southwestern Oncology Group study
109. Teniposide (VM-26) in patients with advanced endometrial cancer: A Phase II trial of the gynecologic oncology group
110. Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the gynecologic oncology group
111. Aminothiadiazole (NSC 4728) in patients with advanced carcinoma of the endometrium. A Phase II study of the Gynecologic Oncology Group
112. A Phase II trial of amonafide in patients with endometrial cancer. A Gynecologic Oncology Group Study
113. A Phase II trial of m-AMSA in the treatment of advanced gynecologic malignancies
114. m-AMSA and adenocarcinoma of the endometrium. A Southwest Oncology Group study
115. Phase II evaluation of dianhydrogalactitol in the treatment of advanced endometrial adenocarcinoma: A gynecologic oncology group study
116. A Phase II clinical trial of diaziquone in the treatment of patients with recurrent endometrial carcinoma. A Gynecologic Oncology Group study
117. Ecninomycin in recurrent or metastatic encomtrial carcinoma: A Phase II trial of the gynecologic oncology group
118. Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced endometrial cancer
119. A Phase II clinical trial of methyl-glyoxal-bisguanylhydrazone (MGBG) in advanced endometrial cancer
120. A randomized comparison of adriamycin with or without cyclophosphamide in the treatment of advanced or recurrent endometrial cancer
121. Doxorubicincyclophosphamide: Effective chemotherapy for advanced endometrial adenocarcinoma
122. Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide
123. A Phase II trial of taxol in advanced and recurrent adenocarcinoma of the endometrium
124. The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix
125. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer
126. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A gynecologic oncology group study
127. Phase III trial of doxorubicin +/-cisplatin in advanced or recurrent endometrial carcinoma: A gynecologic oncology group study
128. An EORTC GCCG randomized Phase II trial of doxorubicin vs. doxorubicin + DDP in endometrial carcinoma
129. Randomized trial of doxorubicin plus cisplatin versus DOX plus paclitaxel plus granulocyte colony-stimulating factor in patients with advanced or recurrent endometrial cancer A report on GOG protocol #163
130. Doxorubicin and cyclophosphamide chemotherapy for disseminated endometrial cancer
131. Adriamycin and cisdiamminedichloroplatinum in the treatment of metastatic endometrial adenocarcinoma
132. Treatment of advanced endometrial carcinoma with doxorubicin and cisplatin: Effects on both untreated and previously treated patients
133. Circadiantimed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma
134. Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin
135. Treatment of advanced or recurrent endometrial adenocarcinoma with cyclophosphamide, doxorubicin, cisplatinum and megestrol acetate
136. Cisplatin, doxorubicin and cyclophosphamide chemotherapy for advanced endometrial carcinoma
137. Treatment of recurrent and metastatic endometrial cancer with cisplatin, doxorubicin, cyclophosphamide and megestrol acetate
138. Treatment of advanced and recurrent endometrial cancer with cisplatin, doxorubicin and cyclophosphamide
139. Use of cisplatin, doxorubicin and cyclophosphamide to treat advanced and recurrent adenocarcinoma of the endometrium
140. Chemotherapy of advanced endometrial carcinoma with cyclophosphamide, adriamycin and cisplatin (CAP)
141. Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin and cyclophosphamide
142. Postoperative Adjuvant Cisplatin, doxorubicin and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma
143. Combination of cisplatin, epirubicin and cyclophosphamide (PEC Regimen) in advanced or recurrent endometrial cancer. A retrospective clinical study
144. Doxorubicincisplatin-vinblastine combination chemotherapy of advanced endometrial carcinoma: A Southwest oncology group study
145. Treatment of advanced or recurrent endometrial carcinoma with combination of etoposide, cisplatin and 5 fluorouracil: A Phase II study
146. Phase II trial of doxorubicin, 5-fluorouracile, etoposide and cisplatin in advanced or recurrent endometrial carcinoma
147. Phase I trial of escalating doses of paclitaxel (TAX) combined with fixed doses of cisplatin (CIS) and doxorubicin (DOX) in patients with advanced gynecologic malignancies: A Gynecologic Oncology Group (GOG) trial
148. Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma
149. A preliminary study of a combination chemotherapy with ifosfamide, adriamycin and cisplatin for endometrial carcinoma
150. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent and histologic high-risk endometrial carcinoma: Preliminary report
151. VM-26-vincristine-cisplatin combination chemotherapy in the treatment of primary advanced and recurrent endometrial carcinoma
152. Phase II study of topotecan and ciplatinum Stage 3 and 4 or for recurrent endometrial cancer
153. Carboplatin and vinorelbine combination for treatment of advanced endometrial carcinoma
154. Phase II trial of methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) in women with advanced endometrial carcinoma
155. Adjuvant chemotherapy with cisplatin, doxorubicin and cyclophosphamide (PAC) for early stage high risk endometrial cancer: A preliminary analysis
156. Adjuvant doxorubicin, cisplatin and etoposide (APE) chemotherapy in high risk endometrial carcinoma
157. Adjuvant cisplatin, doxorubicin and etoposide and pelvic radiotherapy for advanced stage or virulent histologic subtypes of endometrial cancer
158. Cisplatin, doxorubicin hydrochloride and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma
159. Melphalan, 5-flurouracil and medroxyprogesterone acetate in metastatic endometrial carcinoma
160. Treatment of advanced adenocarcinoma of the endometruim with melphalan, 5-fluorouracil and medroxyprogesterone acetate: A preliminary study
161. Chemotherapy of advanced and recurrent endometrial carcinoma with cyclophosphamide, doxorubicin, 5-fluorouracil and megesterol acetate
162. Combination chemotherapy of advanced endometrial adenocarcinoma with adriamycin, cyclophosphamide, 5-fluouracil and medroxyprogesterone acetate
163. Treatment of recurrent and metastatic adenocarcinoma of the endometrium with cisplatin, doxorubicin, cyclophosphamide and medroxyprogesterone acetate
164. Carboplatin, methotrexate and 5-fluorouracil in combination with medroxyprogesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: A Hellenic cooperative oncology group study
165. Phase II trial of cisplatin, adriamycin and etoposide for metastatic endometrial adenocarcinoma
166. Medroxyprogesterone acetate release from silastic devices as replacement for local irradiation by radium tubes in preoperative intrauterine packing for endometrial adenocarcinoma
167. Adjuvant hormone therapy of primary endometrial adenocarcinoma with oxyprogesterone caproate
168. Can primary endometrial carcinoma stage I be cured without surgery and radiation therapy?
169. Hormonal therapy for lesions of the endometrium
170. Leuprolide in the treatment of endometrial cancer
171. Postoperative external irradiation and prognostic parameters in Stage I endometrial carcinoma
172. FIGO stages: 1988 revision
173. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial
174. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer